Clinical Trial Update: The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing changes in bone turnover markers after low-dose alendronate in postmenopausal women with osteoporosis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• FOSAMAX (ALENDRONATE SODIUM)

Snippet

Sponsor: Eulji University Hospital | Conditions: Osteoporosis | Phase 4 | Status: COMPLETED